NTRK fusions are extremely rare in bone tumours

AIMS: Because of the efficacy of tropomyosin receptor kinase (Trk) inhibitor therapy in tumours with rearrangements of the neurotrophic tyrosine kinase receptor genes (NRTK genes), there has been a surge in demand for NTRK fusion screening. To date, most studies involving mesenchymal tumours have fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Suk Wai, Briaire‐de Bruijn, Inge H, van Wezel, Tom, Cleven, Arjen H G, Hogendoorn, Pancras C W, Cleton‐Jansen, Anne‐Marie, Bovée, Judith V M G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596806/
https://www.ncbi.nlm.nih.gov/pubmed/34148257
http://dx.doi.org/10.1111/his.14432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596806/
https://www.ncbi.nlm.nih.gov/pubmed/34148257
http://dx.doi.org/10.1111/his.14432

Ejemplares similares